司库奇尤单抗治疗银屑病关节炎的转录组分析揭示潜在的新型应答相关通路
本研究基于OUTPASS前瞻性观察队列,选取13例接受司库奇尤单抗治疗的银屑病关节炎(PsA)患者,在基线及治疗3个月时进行全血RNA测序,并以DAS28和PsA应答标准评估应答。结果发现IGHV3-64D和IGHV1-46在应答组基线和3个月时差异表达并持续存在,另鉴定出5个潜在驱动基因,提示代谢通路可能调节治疗应答。
要点
- IGHV3-64D和IGHV1-46为司库奇尤单抗应答的基线预测生物标志物。
- 5个重叠基因被鉴定为潜在驱动基因,涉及代谢通路。
- 结论需进一步验证,样本量小。
核心结论
- 鉴定了两个司库奇尤单抗应答的治疗前预测生物标志物,且随时间持续存在。
- 整合WGCNA发现五个额外候选基因,涉及代谢通路,可能调节司库奇尤单抗应答。
研究设计与样本
- 基于OUTPASS前瞻性观察队列,选取13例接受司库奇尤单抗治疗的PsA患者,按极端表型应答选择样本。
- 在基线(治疗前)和治疗3个月时进行全血RNA测序,3个月时用DAS28标准和银屑病关节炎应答标准评估应答。
主要发现
- IGHV3-64D和IGHV1-46在应答组基线、3个月时差异表达并持续存在(校正P < 0.05)。
- 五个重叠基因GMPR、CDC34、DMTN、UBXN6和SLC25A39被鉴定为潜在驱动基因。
- 功能分析提示代谢通路可能参与调节治疗应答。
关键数值与推荐
- 差异表达基因定义为校正P < 0.05且|log2 fold change| ≥ 1。
- 富集通路定义为P < 0.05。
临床怎么用
- IGHV3-64D和IGHV1-46或可作为司库奇尤单抗治疗前应答预测的候选生物标志物。
- 代谢通路相关基因可能为调节司库奇尤单抗应答提供潜在靶点。
局限性
- 样本量小(13例),结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IL-17A inhibitors are therapeutic options in PsA, but response is not universal. Evidence from other inflammatory arthritides suggests differential gene expression may predict the outcomes. This study aimed to identify transcriptomic predictive biomarkers of response in PsA patients commencing secukinumab. METHODS: Participants were recruited to OUtcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS), a prospective observational cohort study of patients with PsA initiating advanced therapeutics. Samples for this analysis were chosen based on extreme phenotype response. Whole-blood RNA sequencing was performed longitudinally in 13 secukinumab-treated patients at baseline (pre-treatment) and at 3 months post-treatment, with response evaluated at 3 months using the DAS28 criteria and the Psoriatic Arthritis Response Criteria. Differential gene expression analysis, Ingenuity Pathway Analysis (IPA), and weighted gene co-expression network analysis (WGCNA) were performed to identify significantly differentially expressed genes (DEGs) (adjusted P < 0.05, |log2 fold change| ≥ 1), enriched pathways (P < 0.05), and co-expressed gene modules. Immune cell subset proportions were estimated by deconvolution, and hub genes were identified by integrating DEGs and WGCNA, with overlapping genes defined as potential driver genes. RESULTS: IGHV3-64D and IGHV1-46 were differentially expressed at baseline, 3 months, and sustained over time in the responder group (adjusted P < 0.05). Five overlapping genes (GMPR, CDC34, DMTN, UBXN6 and SLC25A39) were identified as potential drivers. Functional analysis indicated a potential contribution of metabolic pathways to the modulation of therapeutic response. CONCLUSION: We identified two genes as pre-treatment predictive biomarkers of secukinumab response that persisted over time. Integration with WGCNA revealed five additional candidate genes. These genes are implicated in metabolic pathways, which may modulate the secukinumab response. These findings warrant further validation.
引用
- Abdul Jalil NA, Chinoy H, Jani M, et al. Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways. Rheumatology (Oxford). 2026. PMID: 41987562. doi:10.1093/rheumatology/keag193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。